Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve M-16V + bifidobacterium longum subsp. infantis M-63 + bifidobacterium longum subsp. longum BB536
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A three-strain probiotic mixture comprising human-residential bifidobacteria (HRB) strains: *Bifidobacterium breve* M-16V, *Bifidobacterium longum* subsp. *infantis* M-63, and *Bifidobacterium longum* subsp. *longum* BB536. Developed by Morinaga Milk Industry, this combination is specifically designed to colonize the infant gut and utilize human milk oligosaccharides (HMOs). It is primarily investigated for the prevention of necrotising enterocolitis (NEC) and hospital-acquired infections in extremely preterm infants by promoting a bifidobacteria-predominant intestinal environment and excluding pathogenic bacteria like Enterobacteriaceae. The mixture also demonstrates clinical utility in pediatric conditions such as irritable bowel syndrome, functional dyspepsia, and allergic rhinitis by modulating inflammatory responses and supporting intestinal barrier function.
- Other names
- Morinaga triple-strain probiotic mixtureMorinaga TS probioticHRB probiotic mixtureBifidobacterium probiotic mixture
Beyond the preview
Go deeper on bifidobacterium breve M-16V + bifidobacterium longum subsp. infantis M-63 + bifidobacterium longum subsp. longum BB536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve M-16V + bifidobacterium longum subsp. infantis M-63 + bifidobacterium longum subsp. longum BB536.